CHIH-HSIN YANGSequist L.V.2020-05-262020-05-2620140732-183Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85047688005&doi=10.1200%2fJCO.2013.54.1920&partnerID=40&md5=0287f8c7a95d09ca8540b7f13c79dc80https://scholars.lib.ntu.edu.tw/handle/123456789/495023[SDGs]SDG3afatinib; anaplastic lymphoma kinase; cisplatin; crizotinib; erlotinib; gefitinib; pemetrexed; afatinib; antineoplastic agent; epidermal growth factor receptor; quinazoline derivative; cancer chemotherapy; cancer patient; cancer research; epidermal growth factor receptor gene; Europe; gastrointestinal stromal tumor; genotype; human; intention to treat analysis; letter; lung adenocarcinoma; lung cancer; melanoma; mutator gene; outcome assessment; patient selection; priority journal; solid tumor; systematic review (topic); United States; validation study; adenocarcinoma; female; genetics; lung tumor; male; note; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neoplasms; Male; Quinazolines; Receptor, Epidermal Growth Factorletter10.1200/JCO.2013.54.1920244937342-s2.0-85047688005